Taysha Gene Therapies Inc
TSHA
Market Cap$411.94M
Close$
$-0.18
105.4% downside
Current Fair Value
105.4% downsideOvervalued by 105.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $411.94 Million |
|---|---|
| Enterprise Value | $140.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.96 |
| Beta | 0.38 |
| Outstanding Shares | 232,821,553 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.09 |
|---|---|
| PEG | -14.39 |
| Price to Sales | - |
| Price to Book Ratio | 3.26 |
| Enterprise Value to Revenue | 17.36 |
| Enterprise Value to EBIT | -1.51 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Taysha Gene Therapies Inc
38 employeesTaysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined i...